NASDAQ:ALGS

Aligos Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy ALGS

*Your capital is at risk

$5.14

-0.110 (-2.10%)

At Close: Jun 03, 2026

Aligos Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 6.11M and sold 1.42M ALGS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	6.11M shares
● Sell	1.42M shares
84% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 28, 2024 Buy	Stock Option (Right to Buy) A-Award	Blatt Lawrence Chief Executive Officer	CEO / President	230 999 Value: $221.8K
Feb 28, 2024 Buy	Stock Option (Right to Buy) A-Award	Martell Bridget A Director	Director	8 823 Value: $8K
Feb 28, 2024 Buy	Stock Option (Right to Buy) A-Award	Calhoun Lesley Ann See Remarks	Other	18 750 Value: $18.0K
Feb 28, 2024 Buy	Stock Option (Right to Buy) A-Award	Calhoun Lesley Ann See Remarks	Other	51 833 Value: $49.8K
Feb 28, 2024 Buy	Stock Option (Right to Buy) A-Award	Calhoun Lesley Ann See Remarks	Other	74 998 Value: $72.0K
Feb 28, 2024 Buy	Stock Option (Right to Buy) A-Award	Mcclure Matthew W. Chief Medical Officer	Officer	16 428 Value: $15.8K
Feb 28, 2024 Buy	Stock Option (Right to Buy) A-Award	Mcclure Matthew W. Chief Medical Officer	Officer	65 713 Value: $63.1K
Feb 28, 2024 Buy	Stock Option (Right to Buy) A-Award	Mcclure Matthew W. Chief Medical Officer	Officer	75 183 Value: $72.2K
Feb 28, 2024 Buy	Stock Option (Right to Buy) A-Award	Scopa James Paul Director	Director	8 823 Value: $8K
Feb 27, 2024 Sell	Stock Option (Right to Buy) D-Return	Hirth Peter Director	Director	15 000 Value: $398.7K
Feb 27, 2024 Sell	Stock Option (Right to Buy) D-Return	Scopa James Paul Director	Director	30 000 Value: $873.0K
Feb 27, 2024 Sell	Stock Option (Right to Buy) D-Return	Martell Bridget A Director	Director	30 000 Value: $495.6K
Feb 27, 2024 Sell	Stock Option (Right to Buy) D-Return	Nuechterlein Carole Director	Director	15 000 Value: $398.7K
Feb 27, 2024 Sell	Stock Option (Right to Buy) D-Return	Nielsen Jack Director	Director	15 000 Value: $398.7K
Feb 27, 2024 Sell	Stock Option (Right to Buy) D-Return	Symons Julian A. See Remarks	Officer	200 000 Value: $3.24M
Feb 27, 2024 Sell	Stock Option (Right to Buy) D-Return	Symons Julian A. See Remarks	Officer	26 250 Value: $80.3K
Feb 27, 2024 Sell	Stock Option (Right to Buy) D-Return	Blatt Lawrence Chief Executive Officer	CEO / President	450 000 Value: $7.28M
Feb 27, 2024 Sell	Stock Option (Right to Buy) D-Return	Blatt Lawrence Chief Executive Officer	CEO / President	80 850 Value: $247.4K
Feb 27, 2024 Sell	Stock Option (Right to Buy) D-Return	Calhoun Lesley Ann See Remarks	Other	26 250 Value: $80.3K
Feb 27, 2024 Sell	Stock Option (Right to Buy) D-Return	Martell Bridget A Director	Director	30 000 Value: $495.6K
Feb 27, 2024 Sell	Stock Option (Right to Buy) D-Return	Calhoun Lesley Ann See Remarks	Other	176 237 Value: $2.85M
Feb 27, 2024 Sell	Stock Option (Right to Buy) D-Return	Mcclure Matthew W. Chief Medical Officer	Officer	255 626 Value: $4.14M
Feb 27, 2024 Sell	Stock Option (Right to Buy) D-Return	Mcclure Matthew W. Chief Medical Officer	Officer	23 000 Value: $70.4K
Feb 27, 2024 Sell	Stock Option (Right to Buy) D-Return	Scopa James Paul Director	Director	30 000 Value: $873.0K
Feb 27, 2024 Sell	Stock Option (Right to Buy) D-Return	Hirth Peter Director	Director	15 000 Value: $398.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ALIGOS THERAPEUTICS INC.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The com...

Read Full Profile Here